Canada-based Bioniche (ASX:BNC) has scored an exclusive distribution deal covering four products for its animal health-focused Australian subsidiary. [ + ]

Bionomics (ASX:BNO) has been cleared by the Food and Drug Administration to commence a phase I/II clinical trial of BNC105 as a treatment for ovarian cancer. [ + ]

Avexa Limited (ASX:AVX) and the EMA have agreed on the path forward to gaining European approval for drug-resistant HIV treatment ATC. [ + ]

Australia is a top performer when it comes to science output per capita and per scientist, according to the Nature Publishing Index 2011 Asia-Pacific. [ + ]

The painful side effects of cancer treatment, including nausea and hair loss, could be a thing of the past, thanks to groundbreaking chemical research being conducted at the University of Canterbury. [ + ]

Melbourne's Starpharma Holdings (ASX:SPL) has commenced two phase III trials of VivaGel as a BV treatment, the results of which will be pivotal to its New Drug Application with the FDA. [ + ]

Early bird registration is now available for the 2012 AusMedtech national conference to be held in Sydney, Australia’s medical technology hub. [ + ]

Gold nanoparticles can be used as delivery vehicles for platinum anticancer drugs, improving targeting and uptake into cells, according to research published in this month’s edition of the international journal Inorganic Chemistry. [ + ]

Brisbane-based company Bilexys, originating from The University of Queensland (UQ), has won the Pre-Revenue Track award in the US$200,000 Imagine H20 2011 Prize - the world’s premier competition for water start-up companies. [ + ]

The Raising the Bar Bill that reforms Australia’s intellectual property laws has passed both houses of parliament and will soon be signed into law. [ + ]

Melbourne's HealthLinx (ASX:HTX) has taken another step towards gaining regulatory approval to sell OvPlex in South Korea, by laying the groundwork for a trial. [ + ]

Biota (ASX:BTA) will expand its facilities in Melbourne to allow it to fulfil a $220m contract for the advanced development of a influenza antiviral in the US. [ + ]

Melbourne's Patrys Limited (ASX:PAB) has published the results of a safety and tolerability trial of anti-cancer antibody PAT-SM6. [ + ]

AusBiotech’s 2012 CEO Biotechnology Industry Position Survey will be launched by AusBiotech’s CEO, Dr Anna Lavelle, at the member-only briefings in April. [ + ]

Pharmaxis’ cystic fibrosis treatment Bronchitol is slated to be listed on the Pharmaceutical Benefits Scheme for reimbursement. [ + ]